FOLD — Amicus Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.26bn
- $2.40bn
- $528.30m
- 48
- 27
- 27
- 25
Annual cashflow statement for Amicus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -277 | -250 | -237 | -152 | -56.1 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 66.9 | 70.7 | 105 | 128 | 113 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -32.1 | -28.9 | -39.9 | -48 | -98.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -233 | -202 | -167 | -69.1 | -33.9 |
| Capital Expenditures | -3.23 | -3.88 | -3.77 | -7.44 | -3.55 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -10.4 | 82.6 | 96.1 | 106 | 2.99 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -13.6 | 78.8 | 92.3 | 98.1 | -0.56 |
| Financing Cash Flow Items | -10 | -16.7 | -11.5 | -20.6 | -22 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 263 | 212 | -7.46 | 61.7 | 5.12 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19.8 | 83.3 | -96.3 | 97 | -33.4 |